

Supplement Table S4.

Serum biomarker levels at baseline from patients with non-systemic JIA comparing inactive/active disease and remission off medication/non-achievement of remission at 18-year follow-up.

	Baseline biomarkers all	Baseline biomarkers Clinical examination at 18-year FU	Baseline biomarkers Inactive disease at 18-year FU	Baseline biomarkers Active disease at 18-year FU	p-value	Baseline biomarkers Remission off med at 18-year FU	Baseline biomarkers Not in remission at 18-year FU	p-value
N	226	192	108	78		73	113	
IL-1b	16.5 (6.2-30.5)	16.5 (6.2-32.2)	14.1 (5.7-28.2)	22.1 (8.5-72.0)	0.029	11.7 (1.2-27.1)	21.3 (8.9-58)	0.019
IL-4	88.6 (56.6-132.6)	82.4 (54.0-125)	80.9 (51.9-125.9)	88 (58.3-121.5)	0.351	79.9 (50.6-125.5)	88.3 (56.4-126)	0.472
IL-6	6.7 (3.2-12.6)	6.1 (3.2-11.9)	5.1 (2.7-10.3)	8.0 (3.9-15.2)	0.019	5.1 (2.7-10.2)	7.0 (3.2-13.9)	0.094
IL-10	5.3 (2.3-7.1)	5.0 (1.6-6.8)	4.5 (2.2-6.7)	5.4 (1.5-7.1)	0.291	4.39 (1.29-6.39)	5.4 (2.7-7.2)	0.119
IL-12	13.4 (0.5-72.5)	26.7 (0.5-72.9)	13.2 (0.5-65.5)	50.6 (0.5-94.2)	0.004	1.1 (0.5-69.5)	34.0 (0.5-80.9)	0.040
IL-13	497 (387-621)	497 (386-621)	469 (385-600)	519 (413-677)	0.022	461 (385-578)	507 (406-658)	0.049
IL-17	9.7 (0.8-16.0)	8.0 (0.8-15.2)	6.9 (0.8-15.8)	10.3 (1.9-15.2)	0.343	5.9 (0.7-15.2)	8.0 (1.9-15.2)	0.262
IL-18	198 (136-273)	187 (131-271)	181 (129-238)	201 (130-285)	0.425	185 (123-236)	194 (135-282)	0.422
TNFα	9.2 (2.2-16.6)	7.4 (1.0-14.6)	5.9 (1.0-15.2)	8.9 (3.6-14.6)	0.141	5.5 (1.0-14.8)	8.9 (3.3-14.8)	0.068
MMP-3	5064 (1727-16424)	5174 (1742-16389)	3025 (1630-14009)	7861 (2939-22990)	0.003	2687 (1306-18973)	6903 (2100-16316)	0.035
CCL-2	183 (112-255)	174 (112-251)	165 (109-255)	187 (118-245)	0.545	155 (100-234)	185 (118-260)	0.163
CD25	581 (418-760)	552 (415-737)	550 (421-720)	569 (388-759)	0.845	538 (424-729)	554 (403-745)	0.986
GM-CSF	0.4 (0.4-3.7)	0.4 (0.4-4.2)	0.4 (0.4-3.9)	0.5 (0.4-5.5)	0.067	0.4 (0.4-3.8)	0.4 (0.4-4.6)	0.797
MPO	2289 (1533-3565)	2288 (1499-3418)	2291 (1468-3244)	2624 (1519-3951)	0.262	2353 (1621-3128)	2267 (1477-4021)	0.535
S100A9	505 (309-1055)	501 (300-1018)	441 (272-1018)	636 (380-1155)	0.027	449 (297-1184)	612 (308-1059)	0.185
S100A12	904 (431-1601)	881 (410-1612)	761 (306-1570)	1333 (631-1874)	0.003	828 (293-1608)	1038 (499-1630)	0.098

Values are in picograms (pg)/ milliliter (ml) expressed as median (interquartile range (IQR)). P-values are calculated using Mann-Whitney U test.

*: 108 patients had inactive disease according to Wallace provisional criteria (25) and 78 had active disease. Missing values regarding the criteria were seen in 6 patients.

** : 73 patients achieved remission off medication according to Wallace criteria (26) and 113 patients did not fulfill these criteria of remission. Missing values regarding the criteria were seen in 6 patients.

IL: interleukin, TNF α : tumor necrosis factor alpha; MMP-3: matrix metalloproteinase 3; CCL-2: chemokine ligand 2; GM-CSF: granulocyte-macrophage colony-stimulating factor; MPO: myeloperoxidase; S100A9/A12: S100 calcium-binding protein A9/A12.